Amarin Corp Plc (AMRN)

[north40000]

The scripts may be a big reason accounting for Watson's[AGN's] interest in maintaining a semblance of 1st filer status. Ziploc pointed out yesterday that AGN's Restasis activity in treating DES
leaves something to be desired. Several of us, including me, as well as the literature posted by Zumantu, have pointed out that Vascepa is effective in treating DES. For me, that is definitely off-label use as prescribed by my physician, as a result of info provided by me to him. The 1st Amendment case becomes even more important in that light to enable AMRN to reach physicians with truthful, not misleading, information about that indication.

All of the above could accelerate an AGN interest in a TO for AMRN.